

HETEROCYCLES, Vol. 81, No. 10, 2010, pp. 2239 - 2246. © The Japan Institute of Heterocyclic Chemistry
Received, 10th August, 2010, Accepted, 26th August, 2010, Published online, 26th August, 2010
DOI: 10.3987/COM-10-12042

AN ENANTIO- AND DIASTEREOCONTROLLED SYNTHESIS OF (-)-SALINOSPORAMIDE A

Yosuke Sato, Hayato Fukuda, Masaki Tomizawa, Tomohito Masaki,
Masatoshi Shibuya, Naoki Kanoh, and Yoshiharu Iwabuchi*

Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aobayama,
Sendai 980-8578, Japan. E-mail: iwabuchi@mail.pharm.tohoku.ac.jp

Abstract – The enantio- and diastereocontrolled total synthesis of (-)-salinosporamide A, a potent 20S proteasome inhibitor, was accomplished through organocatalytic aldolization, diastereoselective Claisen condensation, a Rh-catalyzed Reformatsky reaction, and an AZADO-catalyzed oxidative β -lactonization reaction as the key reactions.

Salinosporamide A (**1**, aka NPI-0052, marizobnib) was discovered by Fenical and coworkers as a cytotoxic principle produced by a marine actinomycete *Salinospora tropicana*.¹ Structurally, salinosporamide A has the same unique fused β -lactone- γ -lactam core as omuralide (**2**), a well-known 20S proteasome inhibitor derived from lactacystin (**3**),² but is distinguished by its five contiguous asymmetric centers consisting of a β -chloroethyl group, two quaternary carbons, and a 2-cyclohexene ring. Salinosporamide A has been reported to be approximately 35 times more effective at proteasome inhibition than omuralide,¹ making it as a candidate for the development of anticancer drugs.³ The beneficial pharmacological profile of salinosporamide A coupled with its structural complexity has spurred intense efforts to synthesize it.





Figure 1. Structures of salinosporamide A (**1**), omuralide (**2**), and lactacystin (**3**)

To date, a number of total^{4,5} and formal⁶ syntheses have been accomplished, most of which employ Corey's approach^{4a} to realize the diastereoselective installation of the cyclohexene ring of **1** in the later stage of the synthesis, with the exception of the Nagamitsu-Omura synthesis,^{4e} in which the cyclohexene moiety is mounted in the early stage. We now report the enantio- and diastereocontrolled synthesis of (–)-salinosporamide A (**1**) featuring the extensive adoption of aldol and related reactions, where the cyclohexene ring is installed in the early stage of the synthesis.


Our retrosynthetic analysis of **1** is illustrated in Scheme 1. We set **4** as a logical subgoal, of which the deprotected oxazoline and the methyl ester moieties could serve as suitable intermediates to obtain **1**. Among several possible disconnections, we chose the intermolecular aldol reaction of the ketone **5** and an enolate derived from γ -butyrolactone, which would ultimately allow us to secure the vicinal asymmetric quaternary centers in a diastereocontrolled manner. The quaternary center of the ketone **5** should be secured from the oxazoline **6** via a diastereocontrolled mixed Claisen condensation with an acetyl counterpart. The precursor of the oxazoline **6** was expediently assigned to the known aldol **7**:⁷ the highly diastereocontrolled synthesis of the enantiomeric *ent*-**7** was previously attained via an L-proline-catalyzed aldol reaction of (*S*)-Garner's aldehyde^{8a} and cyclohexanone.



Scheme 1. Retrosynthetic analysis of salinosporamide A (**1**)


The oxazoline **12**, serving as the stereochemical basis throughout the synthesis, was prepared as shown in Scheme 2. In accordance with the procedure developed by Rode,⁷ (*R*)-Garner's aldehyde^{8b} was treated with cyclohexanone in the presence of 20 mol% D-proline in CHCl₃-DMSO (3:1) in 5 °C to give **7** with 81% yield and a high diastereoselectivity of over 98% de, of which the diastereochemical preference is

rationalized by the transition state model **A**.⁷ Upon TMS etherification, triflation of the kinetically generated enolate of **7** afforded **8**. Pd-catalyzed reduction of the triflate **8** employing formic acid gave **9** with concomitant desilylation. The exposure of **9** to a mixture of *c*HCl and AcOEt effected the deprotection of the acetonide and the Boc group to give the corresponding amino-diol, which was then condensed with *p*-chlorobenzoyl chloride to give **10**. Note that the installation of the *p*-chlorobenzoyl group was not the result of a capricious choice (*vide infra*).⁹ Treatment of **10** with a catalytic amount of TEMPO in the presence of PhI(OAc)₂¹⁰ in CH₃CN-H₂O (1:1) led to the selective oxidation of the primary alcohol moiety, which upon treatment with diazomethane gave the methyl ester **11**. The cyclization of **11** to the oxazoline **12** was accomplished in boiling toluene using a catalytic amount of *p*-TsOH and Dean-Stark apparatus.



Scheme 2. Synthesis of oxazoline **12**, equivalent to **6**. *Reagents and conditions:* (a) D-proline (0.2 equiv), cyclohexanone (2 equiv), CHCl₃-DMSO (3:1), 5 °C, 3 d; (b) TMSCl (2 equiv), Et₃N (4 equiv), DMAP (0.1 equiv), CH₂Cl₂, 0 °C, 1.5 h; (c) KHMDS (1.3 equiv), PhNTf₂ (1.1 equiv), THF, -78 to -40 °C, 1 h; (d) Pd(OAc)₂ (0.05 equiv), PPh₃ (0.1 equiv), HCO₂H (2.5 equiv), *n*-Bu₃N (3 equiv), DMF, 60 °C, 12 h; (e) *c*HCl, AcOEt, rt, 0.5 h; (f) *p*-chlorobenzoyl chloride (1.5 equiv), Et₃N (4 equiv), DMAP (0.03 equiv), CH₂Cl₂, rt, 0.5 h; (g) K₂CO₃ (10 equiv), MeOH, rt, 2 h; (h) TEMPO (0.25 equiv), PhI(OAc)₂ (2.6 equiv), MeCN-H₂O (1:1), 0 °C, 15 h; (i) CH₂N₂ in Et₂O, MeOH, 0 °C; (j) *p*-TsOH (0.05 equiv), toluene, Dean-Stark, reflux, 12 h.

Having formed the projected chiral platform **12**, we considered the formation of the vicinal quaternary centers in **1** (Scheme 3). The deprotonation of **12** with lithium diisopropylamide in THF and acylation of the resulting enolate with acetyl chloride afforded the required **13** exclusively with 76% yield. The next step, the attachment of γ -butyrolactone, turned out to be troublesome: all the attempted aldol reactions failed to give even a trace amount of the anticipated product and instead gave 2-acetyl- γ -butyrolactone (**14**) as a major product, indicating the formation of the primary adduct **B** and the prompt collapse via a retro-Claisen reaction. After many unsuccessful trials, we decided to make a detour so as to accommodate the transient oxy-anion species generated by the nucleophilic attack of the enolate counterpart (Scheme 3).




Scheme 3. Synthesis of γ -lactam **20**. *Reagents and conditions* (Ar = *p*-Cl-C₆H₄-): (a) *n*-BuLi (2 equiv), *i*-Pr₂NH (2.2 equiv), THF, -78 °C; AcCl (3 equiv), 15 min; (b) γ -butyrolactone, LDA, THF, -78 °C; (c) NaBH₄ (1.5 equiv), MeOH, -40 °C, 2 h; (d) DHP (5 equiv), PPTS (0.22 equiv), CH₂Cl₂, reflux, 3 h; (e) DIBALH (3 equiv), THF, -5 °C, 9 h; (f) Ac₂O (3 equiv), Et₃N (6 equiv), DMAP (0.1 equiv), CH₂Cl₂, reflux, 3 h; (g) Me₂AlCl in hexane (2 equiv), CH₂Cl₂, 0 °C to rt, 0.5 h; (h) 1-Me-AZADO (0.11 equiv), PhI(OAc)₂ (1.65 equiv), CH₂Cl₂, rt, 12 h; (i) (Ph₃P)₃RhCl (0.05 equiv), α -bromo- γ -butyrolactone (4 equiv), Et₂Zn (4 equiv), THF, -20 °C, 3 h; (j) DBU (1.1 equiv), CH₂Cl₂, 0 °C, 12 h; (k) NaBH₃CN (5 equiv), AcOH-THF (2:1), 0 °C, 6 d; (l) 1,2-propanedithiol (4.2 equiv), cHCl, CF₃CH₂OH, rt, 0.5 h.

To this end, ketone **13** was selectively reduced to the alcohol **15** by treatment with NaBH₄ in MeOH at –40 °C. Upon THP protection, the reduction of the ester moiety with DIBALH, acetylation, and the removal of the THP group, we obtained **16** from **15**. Oxidation of the highly congested alcohol **16** was easily achieved under 1-Me-AZADO¹¹-catalyzed conditions using PhI(OAc)₂ to give **17** as a revised substrate for attaching the γ -butyrolactone moiety. Owing to the challenging steric hindrance of **17**, most of attempted aldolizations including the Mukaiyama aldolization¹² using (4,5-dihydrofuran-2-yloxy)trimethylsilane were unsuccessful and only Shibasaki's protocol¹³ using CuF·3PPh₃·2EtOH/(EtO)₃SiF gave the desired adduct with 8% yield. Eventually, we found that the Honda variant¹⁴ of the Reformatsky conditions gave the best results. Thus, **17** was treated with α -bromo- γ -butyrolactone and Et₂Zn in the presence of 5 mol% Wilkinson's catalyst to give **18a** and **18b** in 31% and 30% isolated yields, respectively. The relative stereochemistry of **18a** was confirmed by X-ray analysis of the corresponding $\Delta^{7,8}$ -hydrogenated derivative.¹⁵ Fortunately, **18a** was cleanly isomerized to the desired epimer **18b** upon treatment with DBU. Detachment of the chlorophenylmethylene portion of **18b** was best effected in a two-step sequence through the convenient formation of γ -lactam: (1) reduction of oxazoline with NaBH₃CN^{4a} to form **19** via an intramolecular transactamization, (2) removal of the *p*-chlorobenzylidene group with *c*HCl and 1,3-propanedithiol¹⁶ to give **20**. It should be stressed that the *p*-methoxy counterpart^{4a} of **18b** was significantly resistant⁹ to reduction, resulting in a significant yield loss (Scheme 3).

To progress from **20** to (–)-**1** (Scheme 4), the primary and secondary hydroxyl groups had selectively to be protected in a discriminable manner, with the acetate group detached, of which purpose was expediently attained via the selective TBDPS etherification, deacetylation, selective TMS etherification of the primary and secondary hydroxyl groups, and selective removal of the primary TMS ether on treatment with silica gel to furnish **21**. Fortunately, upon the attempted oxidation of the primary alcohol under AZADO¹¹-catalyzed conditions using PhI(OAc)₂, **21** directly afforded β -lactone **22**. Note that the use of TEMPO¹⁷ significantly retarded the formation of β -lactone. Global deprotection of the silyl groups in **22**, followed by treatment of the resulting diol with Ph₃PCl₂^{4a} finally gave (–)-salinosporamide A. The specific rotation, melting point, and spectroscopic properties of the synthetic **1** were full accordance with the reported data.

In conclusion, we have developed an enantio- and diastereocontrolled route to synthesize (–)-salinosporamide A from (*R*)-Garner aldehyde. The key features of the synthetic route are the Rh-catalyzed Reformatsky reaction of **17** to **18**, and the simple, one-step, oxidative β -lactonization of **22** catalyzed by AZADO. Additional information on the chemo- and diastereoselective manipulations

around the β -lactone- γ -lactam motif should provide useful insight for the design and synthesis of advanced 20S proteasome inhibitors related to salinosporamide A/lactacystin.



Scheme 4. Total synthesis of salinosporamide A (**1**). *Reagents and conditions:* (a) TBDPSCI (10 equiv), Et_3N (30 equiv), DMAP (2 equiv), CH_2Cl_2 , rt, 12 h; (b) Amberlyst-26, MeOH, rt, 2.5 h; (c) TMSCl (5 equiv), Et_3N (10 equiv), DMAP (0.5 equiv), CH_2Cl_2 , rt, 12 h; SiO_2 , CHCl_3 -AcOEt, 15 min; (d) AZADO (0.07 equiv), $\text{PhI}(\text{OAc})_2$ (4 equiv), CH_2Cl_2 , rt, 4 h; (e) aq. HF, MeCN, rt, 1.5 h; (f) Ph_3PCl_2 (17 equiv), pyridine-MeCN (1:1), rt, 2 h.

ACKNOWLEDGEMENTS


This work was financially supported in part by a Grant-in-Aid for Scientific Research on Priority Areas 180320110 and Grant-in-Aid for Global COE Program for “International Center of Research & Education for Molecular Complex Chemistry” from Ministry of Education, Culture, Sports, Science, and Technology, Japan.

REFERENCES AND NOTES

1. R. H. Felig, G. O. Buchanan, T. J. Mincer, C. A. Kauffman, P. R. Jensen, and W. Fenical, *Angew. Chem. Int. Ed.*, 2003, **42**, 355.
2. (a) S. Omura, T. Fujimoto, K. Otoguro, K. Matsuzaki, R. Moriguchi, H. Tanaka, and Y. Sasaki, *J. Antibiot.*, 1991, **44**, 113; (b) S. Omura, K. Natsuzaki, T. Fujimoto, K. Kosuge, T. Furuya, S. Fujita, and A. Nakagawa, *J. Antibiot.*, 1991, **44**, 117.
3. (a) D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades,

- H, Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T.-H. Chao, S. T. C. Neuteboom, P. Richardson, M. A. Palladino, and K. C. Anderson, *Cancer Cell*, 2005, **8**, 407; (b) V. R. Macherla, S. S. Mitchell, R. R. Manam, K. A. Reed, T.-H. Chao, B. Nicholson, G. Deyanat-Yazdi, B. Mai, P. R. Jensen, W. Fenical, S. T. C. Neuteboom, K. S. Lam, M. A. Palladino, and B. C. M. Potts, *J. Med. Chem.*, 2005, **48**, 3684; (c) W. H. Fenical, P. R. Jensen, M. A. Palladino, K. S. Lam, G. K. Lloyd, and B. C. Pott, *Bioorg. Med. Chem.*, 2009, **17**, 2157; (d) A. V. Singh, M. A. Palladino, G. K. Lloyd, B. C. Potts, D. Chauhan, and K. C. Anderson, *Br. J. Heamatol.*, 2010, **149**, 550.
4. Enantioselective synthesis; (a) L. R. Reddy, P. Saravanan, and E. J. Corey, *J. Am. Chem. Soc.*, 2004, **126**, 6230; (b) A. Endo and S. J. Danishefsky, *J. Am. Chem. Soc.*, 2005, **127**, 8298; (c) T. Ling, V. R. Macherla, R. R. Manam, K. A. McArthur, and B. C. M. Potts, *Org. Lett.*, 2007, **9**, 2289; (d) K. Takahashi, M. Midori, K. Kawano, J. Ishihara, and S. Hatakeyama, *Angew. Chem. Int. Ed.*, 2008, **47**, 6244; (e) T. Fukuda, K. Sugiyama, S. Arima, Y. Harigaya, T. Nagamitsu, and S. Omura, *Org. Lett.*, 2008, **10**, 4239; (f) H. Nguyen, G. Ma, and D. Romo, *Chem. Commun.*, 2010, **46**, 4803.
5. Racemic synthesis; (a) N. P. Mulholland, G. Pattenden, and I. A. S. Walters, *Org. Biomol. Chem.*, 2006, **4**, 2845; (b) G. Ma, H. Nguyen, and D. Romo, *Org. Lett.*, 2007, **9**, 2143.
6. Formal synthesis; (a) V. Caubert, J. Massé, P. Retailleau, and N. Langlois, *Tetrahedron Lett.*, 2007, **48**, 381; (b) I. V. Margalef, L. Rupnicki, and H. W. Lam, *Tetrahedron*, 2008, **64**, 7896; (c) T. Momose, Y. Kaiya, N. Hama, J. Hasegawa, T. Sato, and N. Chida, *Synthesis*, 2009, 2983; (d) R. A. Mosey and J. J. Tepe, *Tetrahedron Lett.*, 2009, **50**, 295; (e) J. R. Struble and J. W. Bode, *Tetrahedron*, 2009, **65**, 4957; (f) T. Ling, B. C. Potts, and V. R. Macherla, *J. Org. Chem.*, 2010, **75**, 3882.
7. I. Kumar and C. V. Rode, *Tetrahedron: Asymmetry*, 2007, **18**, 1975.
8. (a) P. Garner and J. M. Park, *J. Org. Chem.*, 1987, **52**, 2361; (b) A. McKillop, R. J. K. Taylor, R. J. Watson, and N. Lewis, *Synthesis*, 1994, 31.
9. Y. Kaburagi, H. Osajima, H. Tokuyama, and T. Fukuyama, *Tetrahedron Lett.*, 2004, **45**, 3817.
10. A. De Mico, R. Margarita, L. Parlanti, A. Vescovi, and G. Piancatelli, *J. Org. Chem.*, 1997, **62**, 6974.
11. (a) M. Shibuya, M. Tomizawa, I. Suzuki, and Y. Iwabuchi, *J. Am. Chem. Soc.*, 2006, **128**, 8412; (b) Y. Iwabuchi, *J. Syn. Org. Chem. Jpn.*, 2008, **66**, 1076.
12. K. Narasaka, K. Banno, and T. Mukaiyama, *Chem. Lett.*, 1973, 1011.
13. K. Oisaki, Y. Suto, M. Kanai, and M. Shibasaki, *J. Am. Chem. Soc.*, 2003, **125**, 5644.
14. K. Kanai, H. Wakabayashi, and T. Honda, *Org. Lett.*, 2000, **2**, 2549.
15. $\Delta^{7,8}$ -H₂-**18a** was prepared from $\Delta^{7,8}$ -H₂-**17**, together with $\Delta^{7,8}$ -H₂-**18b**, under the same Honda-Reformatsky reaction conditions. The relative stereochemistry of $\Delta^{7,8}$ -H₂-**18b** was

confirmed by observing the n.O.e of $\Delta^{7,8}$ -H₂-**19**.



Full account of our synthetic venture toward salinosporamide A will be reported elsewhere.

16. E. J. Corey and G. A. Reichard, *J. Am. Chem. Soc.*, 1992, **114**, 10677.
17. (a) T. M. Hansen, G. J. Florence, P. Lugo-Mas, J. Chen, J. N. Abrams, and C. J. Forsyth, *Tetrahedron Lett.*, 2003, **44**, 57; (b) M. Ebine, Y. Suga, H. Fuwa, and M. Sasaki, *Org. Biomol. Chem.*, 2010, **8**, 39.